Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, Panayiotidis P, Delimpasi S, Michalis E, Anargyrou K, Gavriatopoulou M, Stefanoudaki A, Tzenou T, Koulieris E, Sachanas S, Dimou M, Vassilakopoulos TP, Angelopoulou MK, Pangalis GA, Kyrtsonis MC.
Maltezas D, et al. Among authors: vassilakopoulos tp.
Hematol Oncol. 2013 Jun;31(2):96-102. doi: 10.1002/hon.2026. Epub 2012 Sep 7.
Hematol Oncol. 2013.
PMID: 22961993